With the performance of PSM analysis, the heterogeneous profile of prognosis kept stable in HER2-positive breast cancer associated with HR status, which both the OS and BCSS were in favor of HR-positive subtype (3-year and 5-year OS, 87.4% vs. 86.0% and 80.0% vs. 78.9%, P = 0.015; 3-year and 5-year BCSS, 92.0% vs. 90.6% and 87.3% vs. 86.1%, P = 0.0017) (Figure S1a, b). This evidence concerns the gene ERBB2 and breast carcinoma.